Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Auris Initiates Second Phase III For Pipeline-Leading Hearing Loss Drug

Executive Summary

Auris Medical Holding AG has moved its hearing loss therapeutic, AM-111, into a second Phase III study, making it the most advanced drug in the pipeline for the treatment of sudden deafness, according to Biomedtracker.

Advertisement

Related Content

Auris' Outlook Bleak In Tinnitus After Failure Of Initial Phase III Trial

Topics

Advertisement
UsernamePublicRestriction

Register

SC065457

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel